Summarized by Masters of Longevity from PR Newswire.
Market analysis of retinitis pigmentosa highlights growing clinical pipelines, genetic testing adoption, and emerging disease-modifying therapy strategies for inherited retinal disorders.
Key Takeaways
- Voretigene neparvovec remains the only FDA-approved gene therapy for an inherited retinal disease linked to biallelic RPE65 mutations.
- MeiraGTx/Johnson & Johnson plan to file a BLA and MAA for botaretigene sparoparvovec targeting RPGR-linked XLRP according to their 2026 presentation.
- Beacon Therapeutics reported 12-month safety and efficacy data for laruparetigene zovaparvovec from the Phase 2 DAWN trial presented at ARVO 2026.
